CLINICAL-VALUE OF SDI TEST FOR PREDICTING EFFECT OF POSTOPERATIVE CHEMOTHERAPY FOR PATIENTS WITH GASTRIC-CANCER

被引：7

作者：

BABA, H

TAKEUCHI, H

INUTSUKA, S

YAMAMOTO, M

ENDO, K

OHNO, SJ

MAEHARA, Y

SUGIMACHI, K

机构：

[1] Cancer Center, Faculty of Medicine, Kyushu University, Fukuoka

[2] Department of Surgery Ii, Faculty of Medicine, Kyushu University, Fukuoka

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1994年 / 10卷 / 02期

关键词：

CHEMOSENSITIVITY; SDI TEST; GASTRIC CANCER; PROGNOSIS;

D O I：

10.1002/ssu.2980100216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We retrospectively evaluated the clinical usefulness of the succinate dehydrogenase inhibition (SDI) test as a chemosensitivity test, using 168 resected specimens of gastric cancer, with special reference to the correlation between the results of the SDI test and clinical effects of the corresponding chemotherapy. The rate of sensitivity of these tissues to DDP, CQ, ACR, MMC, ADM, and 5-FU were 63.5%, 54.2%, 47.4%, 42.9%, 31.4%, and 10.8%, respectively. Survival rates for patients with a positive chemosensitivity to MMC and postoperatively prescribed more than 20 mg of MMC were significantly better than those without sensitivity to MMC, even when treated with MMC, although no statistical differences existed in clinicopathologic factors between the two groups. We conclude that the SDI test for human gastric cancer is a rapid, reliable, and useful assay to determine the compatibility between the results of assay and the clinical effects of corresponding chemotherapy. We propose that the regimen of postoperative adjuvant chemotherapy therapy be tailored according to results of the SDI test, using tissues resected from individual patients. (C) 1994 Wiley-Liss, Inc.

引用

页码：140 / 144

页数：5

共 18 条

[1]

Baba H, Korenaga D, Okamura T, Et al., Prognostic factors in gastric cancer, Arch Surg, 124, pp. 1061-1064, (1989)

[2]

Higgins G, Amadeo J, Smith D, Efficacy of prolonged intermittent therapy with combined 5‐FU and methyl‐CCNU following resection for gastric carcinoma, Cancer, 52, pp. 1105-1112, (1983)

[3]

Allum W, Hallissey N, Kelly K, pp. 571-574, (1989)

[4]

Maehara Y, Anai H, Kusumoto H, Sugimachi K, Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma, Eur J Surg Oncol, 13, pp. 203-206, (1987)

[5]

Maehara Y, Kohnoe S, Sugimachi K, Chemosensitivity test for carcinoma of digestive organs, Semin Surg Oncol, 6, pp. 42-47, (1990)

[6]

Kusumoto H, Maehara Y, Kusumoto T, Et al., Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer, Eur J Surg Oncol, 14, pp. 685-689, (1988)

[7]

Kusumoto H, Maehara Y, Yoshida M, Et al., Relationship between tumor histopathology and in vitro sensitivity to antitumor drugs in gastric cancer, Anticancer Drugs, 3, pp. 33-38, (1992)

[8]

Kohnoe S, Emi Y, Sakaguchi Y, Et al., The microtiter SDI test is more advantageous than the SDI test for assessing the chemosensitivity of human tumor cells, Anticancer Drugs, 2, pp. 145-152, (1991)

[9]

The general rules for the gastric cancer study in surgery and pathology, Jpn J Surg, 11, pp. 127-145, (1981)

[10]

Mosmann T, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J Immunol Meth, 65, pp. 55-63, (1983)

← 1 2 →